Abstract-Coronary heart disease is the leading cause of death in the United States. Heart disease can take many forms, the most severe of which is myocardial infarction (MI), also known as heart attack. Ventricular restoration (VR) is an approach to treating MI that involves excising the infarction and replacing it with a cardiac patch to restore the heart to a more natural shape. Commercially available patches such as Dacron and ePTFE are passive and do not contribute to the work of the heart once implanted. We propose the design of a new myocardial patch for VR that will induce regeneration and improve long-term heart function. To this end, we have undertaken an iterative design process to develop the required characteristics of such a patch. A composite scaffold design was developed that is composed of an endocardial patch to provide mechanical stability and an injectable filler material that will induce myocardial regeneration. The outcome of this project is the final design of a patch for ventricular restoration that is intended to regenerate myocardium and improve heart function.
I. INTRODUCTION
Myocardial infarction (MI) is a leading killer in the United States; complications following MI can lead to progressive heart failure, ventricular remodeling, and aneurysm [1] . Current treatments for secondary care of MI are aimed solely at preventing recurrence of MI and reducing mortality. Ventricular restoration (VR) is an approach to treating MI that involves excising the infarction and replacing it with a cardiac patch to restore the efficient ellipsoid shape of the heart [2] . Commercially available patches are passive; they neither contribute to the work done by the heart, nor assist in regeneration of myocardium [3] . We propose the design of a new patch for VR that will induce regeneration in order to improve long-term heart function. A composite scaffold design was developed to include an endocardial patch for conventional VR, and an injectable scaffold intended to induce myocardial regeneration by recruiting native bone marrow cells (BMCs) to migrate and differentiate into new myocytes.
II. MATERIALS
For the patch component, Hemashield woven fabric (Boston Scientific), Veritas bovine pericardium-derived collagen matrix (Synovis Surgical), urinary bladder matrix (UBM), and collagen film were chosen for preliminary testing. For the filler material, fibrin gel was chosen. Fibrin gel was manufactured using fibrinogen and thrombin from bovine plasma (Sigma-Aldrich) and seeded with human mesenchymal stem cells (hMSCs; Cambrex).
III. METHODS
Scaffold materials were punched into dog bone shaped samples with dimensions based on ASTM standards and subjected to uni-axial tensile testing. The specification for wall tension was determined based on the Law or Laplace for thin walled cylinders. In addition, as it may be important for the differentiation of cardiac precursor cells to experience the mechanical stretch normally seen in the ventricular wall, a minimum specification of 10% stretch (under uni-axial loading) at a load of 1.37N/mm was specified. In addition, the prospective materials were screened for suture retention strength Fibrin gels were formed using a method similar to that described by Tuan et al. [4] . The formulation of the gel was optimized by measuring migration of hMSCs when fibrinogen concentrations of 3, 5, and 9 mg/ml were used. Migration was assessed according to the method described by Greiling et al. [5] .
IV. RESULTS AND DISCUSSION
The endocardial patch materials were considered to be acceptable for this application if they met the specification established for suture retention and tensile resistance. The specification for tensile resistance was 1.37N/mm and the specification for suture retention was 2.74N, both of which include a safety factor of 5 [6, 7] . With a sample width of 3mm, Veritas, and UBM successfully withstood a tensile force of 4.11N before failing (Fig. 1) , thus meeting the specification.
The stretch ratio of Veritas and UBM feel within the required specification. Preliminary results showed that both Veritas and UBM had a stretch ratio of about 20% when a uniaxial load of 1.37N/mm was applied. Hemashield, Veritas, and UBM successfully withstood suture retention at 2.74N (Fig. 2) . The collagen membranes were very fragile to handle and were thus eliminated from further testing. 
V. CONCLUSIONS
The collagen membranes proved to be unsuitable for endocardial patch applications. Further characterization testing must be conducted on Hemashield, Veritas, and UBM to determine their suitability in a cardiac environment.
Due to the observed absence of cell migration in the fibrin gels, the next step of this project is to incorporate granulocyte colony-stimulating factor (G-CSF) in an effort to stimulate cell migration. It is our hypothesis that the use of G-CSF will encourage the migration and proliferation of hMSCs and allow them to differentiate into new cardiogenic cells.
